cantly less IFNβ and CXCL10 expression in the spleen and plasma than WT mice. These studies suggest that thrombin activation of PAR-1 contributes to the antiviral response in mice.
RNA virus replication [1] . dsRNA is detected by the transmembrane receptor toll-like receptor (TLR)3, as well as the cytosolic receptors dsRNA-dependent protein kinase, retinoic acid-inducible gene I and melanoma differentiation-associated gene 5 [2, 3] . The dsRNA mimetic polyinosinic:polycytidylic acid (poly I:C) is used experimentally to stimulate TLR3 and induce the expression of type I IFNs in vitro and in vivo [1, [3] [4] [5] .
TLR3 is broadly expressed by myeloid and nonmyeloid cells [3, 6] . Within the spleen, high levels of TLR3 expression are present in the cells of the red pulp as well as in the marginal zone, while lower levels of expression are present in macrophages and dendritic cells (DCs) in the white pulp [6] . TLR3-dependent innate immune activation is essential to fight particular virus infections, including poliovirus, rhinovirus, herpes simplex, encephalomyocarditis and Coxsackievirus group B (CVB) [3] . In addition, TLR3 enhances the antiviral responses of macrophages against other viruses, such as the monkey and human immunodeficiency viruses (HIV) [7, 8] .
Virus infections activate the coagulation system by inducing tissue factor (TF) expression in various cell types [9] [10] [11] . Interestingly, one study found that poly I:C induced TF expression in endothelial cells but not monocytes [12] . Furthermore, administration of poly I:C to mice increased systemic activation of coagulation and fibrin deposition in the liver in a TLR3-dependent manner [12] . Thrombin is the central protease of the coagulation cascade but also activates cells by cleavage of proteaseactivated receptors (PARs), such as PAR-1 [13] . This receptor is also activated by other proteases, such as matrix metalloproteinases (MMP)1 and MMP13 [4, 9, 10, 14, 15] . PAR-1 is expressed by a variety of human and murine immune cells, including monocytes/macrophages, DCs, T cells and NK cells [16, 17] .
The coagulation and immune systems appear to have a common evolutionary origin [18] . Moreover, there is crosstalk between these two systems during infections [9, 10, 17, 18] . It has been proposed that TLRs and PARs act as a cooperative sensor system to detect pathogens [10, 19] . We demonstrated that PAR-1 activation enhanced poly I:C-induced IFNβ and CXCL10 expression in murine cardiac fibroblasts, suggesting an interaction between PAR-1 and TLR3 [4] . In a CVB3 mouse model, we observed that a deficiency of PAR-1 was associated with reduced type I IFN responses, leading to increased myocarditis [4] . In addition, inhibition of the PAR-1 activating proteases thrombin or MMP13 led to increased myocarditis [4] . Bone marrow transplantation experiments further revealed that PAR-1 on both nonhematopoietic and hematopoietic cells contributed to PAR-1 mediated protection against CVB3 myocarditis [4] . This finding is consistent with the observation that cardiac damage and survival of CVB4-infected TLR3-deficient mice can be improved by the adaptive transfer of wild-type (WT) macrophages [20] .
In this study, we utilized poly I:C as a surrogate for viral activation and PAR-1 -/-mice to investigate the role of PAR-1 in the induction of an antiviral innate immune response in macrophages and mice.
Material and Methods

Mice
We used WT and PAR-1 -/-mice on a C57BL/6J background [21] . All mouse studies were performed with the approval of the University of North Carolina at Chapel Hill Institutional Animal Care and Use Committee.
Isolation and in vitro Stimulation of Macrophages, DCs and Splenocytes
WT and PAR-1 -/-mice (4 mice each, aged 8-12 weeks) were used to isolate splenocytes or generate bone marrow-derived macrophages and dendritic cells (BMMs and BMDCs). Each isolation was repeated once. For splenocyte isolation, spleens were harvest and passed through a 70-μm cell strainer to generate a single-cell suspension. Red blood cells were lysed and the splenocytes washed and resuspended at a density of 1 × 10 6 cells per well of a 24-well plate in RPMI 1640 with 10% FBS and 1% penicillin/streptomycin. Cells were stimulated with 25 μg/ml poly I:C (γ-radiated; SigmaAldrich, St. Louis, Mo., USA) and/or PAR-1 agonist peptide (TFLLR-NH 2 , 200 μ M , Abgent, San Diego, Calif., USA) for 2 h.
BMMs were generated from bone marrow using the L929-conditioned media method as described [22] . BMDCs were derived from bone marrow using GM-CSF and IL-4 (30 ng/ml each) as described [23] . RAW264.7 cells, a murine macrophage cell line, were maintained as described [24] .
For experiments, BMMs were plated at a density of 1 × 10 6 cells per well of a 12-well plate the day before stimulation. The next day, cell culture media was replaced with 0.5 ml fetal bovine serum (FBS)-free media and the cells were stimulated with poly I:C (25 μg/ml) and/or PAR-1 agonist peptide (200 μ M ) for different times. BMDCs were seeded in FBS-containing culture media at a density of 1 × 10 6 cells in 1 ml of media the day before stimulation. The next day, cells were stimulated without changing the media with poly I:C (25 μg/ml) and/or PAR-1 agonist peptide (200 μ M ) for 8 h. RAW264.7 cells were seeded at a density of 5 × 10 5 cells per well of a 12-well plate 1 day prior to stimulation. Media was replaced with 0.5 ml FBS-free culture media the next day and the cells were stimulated with 5 μg/ml poly I:C and/or 150 μ M PAR-1 agonist peptide for the indicated times.
For measuring IFNβ promoter activity, RAW264.7 cells were stable-transfected with the pNiFty2-IFB-SEAP plasmid (containing the Ifnb1 promoter) with Zeocin selection (Invivogen, San Diego, Calif., USA) using Lipofectamine 2000 (Life Technologies, Carlsbad, Calif., USA) [4] . Cells were seeded and treated with poly I:C (5 μg/ml) and/or 5 n M of thrombin (human α-thrombin; Enzyme Research Laboratories, South Bend, Ind., USA) as mentioned above. The next day, media was collected, and SEAP (secreted embryonic alkaline phosphatase) activity was detected using QUAN-TI-blue (Invivogen) at 640 nm with a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, Calif., USA) [4] .
In vivo Stimulation
Male mice (8-12 weeks old) were injected intraperitoneally (i.p.) with 8 mg/kg poly I:C (Sigma-Aldrich) diluted in PBS [25] . Blood was collected from the inferior vena cava and plasma was prepared as previously described [11, 26] .
Thrombin Inhibition
To inhibit thrombin, mice were fed for 7 days with a custommade chow (AIN-93M, Dyets Inc., Bethlehem, Pa., USA) with peanut flavoring (2 g/kg chow) with or without dabigatran etexilate (10 g/kg chow) as described [4] . The level of anticoagulation was measured as described [4] .
CVB3 Infection Model
A standard CVB3 infection model was used [4, 5, 27] . Briefly, male mice (aged 6-8 weeks) were infected with an i.p. injection of CVB3 Nancy Strain (10 5 plaque-forming units in 200 μl saline). Tissue and blood were collected and analyzed 4 days after infection. Real-Time PCR Total RNA from cultured cells or splenic tissue was isolated by the TRIzol method (Life Technologies). One microgram of RNA was reverse-transcribed into cDNA using the iScript TM RT Supermix (Bio-Rad Laboratories, Hercules, Calif., USA) [28, 29] . Realtime PCR primer/probes for IFNβ, IFNγ, CXCL10, CCL5, CXCL1, IRF3, IRF7, viperin, Rpl4, GAPDH and 18S were purchased from Integrated DNA Technologies (Coralville, Ia., USA). CVB3 genome levels were quantified as recently described [4, 5] . Real-time PCR reactions were performed using the SSoFast TM Advanced Universal Supermix in a BioRad cycler (Bio-Rad Laboratories). The housekeeping genes Rpl4 or 18S (for splenic tissue) and GAPDH (for cells) were used to correct for variations in input RNA and reaction efficiency [11] .
ELISA IFNβ (PBL Assay Science, Piscataway, N.J., USA), CXCL10, CCL5 and CXCL1 (Duo-Set, R&D Systems, Minneapolis, Minn., USA) ELISAs were used to measure levels of IFNβ and CXCL10, CCL5 and CXCL1 in plasma and/or cleared cell culture supernatant (500 g , 10 min, 4 ° C) [4] .
Statistics
All statistical analyses were performed using GraphPad Prism (v5.0; GraphPad Software Inc., La Jolla, Calif., USA). Data are represented as mean ± SEM. For 2-group comparison of continuous data, 2-tailed Student's t test was used. For multiple-group comparison, data were analyzed by 1-or 2-way ANOVA and Bonferroni's correction was used for repeated measures over time. A p value <0.05 was considered significant.
Results
PAR-1 Activation Enhances Poly I:C Induction of IFNβ and CXCL10 Expression in Murine Macrophages and Splenocytes
Macrophages and DCs are known to reside in the spleen and respond to TLR3 stimulation by expressing IFNβ and CXCL10 [25, 30, 31] . In addition, depletion of phagocytic splenic macrophages and DCs of the marginal zone markedly reduce antiviral responses [32] . We analyzed the role of PAR-1 in the poly I:C induction of IFNβ and CXCL10 expression in the murine macrophage cell line RAW264.7, BMMs, BMDCs and splenocytes from WT and PAR-1 -/-mice. Poly I:C induction of IFNβ promoter activity and IFNβ and CXCL10 mRNA and protein expression in RAW264.7 cells were significantly enhanced by PAR-1 activation ( fig. 1 a-d) . Next, we analyzed poly I:C induction of IFNβ mRNA expression and CXCL10 protein expression in BMMs derived from WT and PAR-1 -/-mice. Poly I:C alone induced IFNβ mRNA expression in both WT and PAR-1 -/-BMMs and splenocytes, but the PAR-1 agonist peptide alone had no effect ( fig. 1 e, g ). Importantly, costimulation of cells with poly I:C and the PAR-1 agonist peptide significantly increased IFNβ mRNA expression in WT BMMs and splenocytes but not in PAR-1 -/-BMMs and splenocytes ( fig. 1 e, g ). In addition, poly I:C stimulation of WT and PAR-1 -/-BMMs induced CXCL10 expression, which was significantly increased in WT BMMs but not PAR-1 -/-BMMs costimulated with PAR-1 agonist peptide ( fig. 1 f) . We did not detect any CXCL10 expression in splenocytes after 2 h of poly I:C stimulation.
Poly I:C-stimulated PAR-1 -/-BMMs and BMDCs expressed lower levels of CXCL10 than WT BMMs and BMDCs ( fig. 1 f; data not shown). This result is consistent with previous studies showing that the poly I:C stimulation of cardiac fibroblasts induces the expression of MMP13 that activates PAR-1 [4, 10] . Similar results were observed for CXCL10 protein expression (8 h) with WT and PAR-1 -/-BMDCs (data not shown). Recently, we observed increased levels of CXCL1 in the lungs of influenza A virus-infected PAR-1 -/-mice compared to WT mice [4] . In addition, IL-8, the human homolog of murine CXCL1, is directly induced after TLR3 stimulation [33] . Therefore, we analyzed CXCL1 expression after poly I:C and/or PAR-1 stimulation in vitro. Poly I:C induced CXCL1 by splenocytes but PAR-1 stimulation alone had no effect ( fig. 1 h) . Unexpectedly, WT splenocytes exhibited 3-fold lower levels of CXCL1 mRNA after stimulation with poly I:C compared to stimulated PAR-1 -/-splenocytes ( fig. 1 h) . Furthermore, activation of PAR-1 in WT splenocytes but not in PAR-1 -/-splenocytes significantly reduced the poly I:C induction of CXCL1 mRNA expression ( fig. 1 h) .
Poly I:C Induces an Antiviral Response in WT Mice
Poly I:C injection in mice leads to maximum type I IFN expression for between 2 and 4 h in the plasma [25, 34] . In addition, poly I:C-mediated synthesis of IFNβ is followed by an increase in CXCL10 plasma levels [34] . In our mouse studies, we focused on changes in gene expression in the spleen due to the presence of blood and lymphoid elements as well as the role of poly I:C in initiating antiviral responses to blood-borne pathogens [25] . We also measured immune mediators in the plasma. To model virus-like infection of mice, WT mice were injected with poly I:C (8 mg/kg) i.p.. The expression of IFNβ, IFNγ, CXCL10, CCL5, CXCL1, IRF7 and viperin mRNA increased in the spleen after the poly I:C injection ( fig. 2 ah ). Maximal levels of these different immune mediators were observed at different times. The different gene expression pattern can be divided into early (IFNβ, CXCL10 and CXCL1), intermediate (IRF7 and viperin) and late (IFNγ). However, we did not observe any changes in the splenic IRF3 mRNA expression after poly I:C injection ( fig. 2 f) . Next, we analyzed the time-dependent changes in protein expression in the spleen. Maximal levels of IFNβ were observed 2 h after the poly I:C injection ( fig. 3 a) . Similar kinetics of IFNβ expression were observed in the plasma ( fig. 4 a) . IFNβ induces several antiviral response genes, such as CXCL10 and CCL5 [5, 33, 34] . In addition, poly I:C induces IL-8 expression [33] . Poly I:C increased levels of CXCL10, CCL5 and CXCL1 in the spleen ( fig. 3 c, e, g ). Maximal levels of IFNβ and CXCL1 were observed at 2 h whereas CXCL10 and CCL5 peaked at later times. Similar results were observed for the expression of these antiviral proteins in the plasma ( fig. 4 c, e, g ).
PAR-1 Deficiency Is Associated with Reduced Poly I:C Induction of Antiviral Proteins in the Spleen and Plasma
Recently, we observed that PAR-1 expression on both nonhematopoietic and hematopoietic cells contributed to antiviral responses against the single-strand RNA virus CVB3 in mice [4] . To determine if PAR-1 contributes to innate immune responses to poly I:C in vivo, WT and PAR-1 -/-mice were injected with poly I:C and the immune response in the spleen and plasma was analyzed. A deficiency of PAR-1 was associated with significantly lower levels of poly I:C-dependent induction of IFNβ, IFNγ, CXCL10, IRF7 and viperin but not CCL5 mRNA expression ( fig. 2 i) . In line with our in vitro data, we observed significantly higher levels of CXCL1 mRNA in PAR-1 -/-spleens than in WT spleens ( fig. 2 i) . In addition, PAR-1 -/-mice injected with poly I:C had significantly lower splenic IFNβ protein levels than WT mice at 2 h but not 4 h ( fig. 3 b) . The level of splenic CXCL10 protein in 
PAR-1
-/-mice was also significantly lower at 2 and 4 h after poly I:C injection than in WT mice ( fig. 3 d) . In addition, CCL5 protein levels were lower in the spleens of PAR-1 -/-mice injected with poly I:C when compared to WT mice ( fig. 3 f) . Consistent with the changes in splenic CXCL1 mRNA levels, CXCL1 protein levels in the spleens of PAR-1 -/-mice injected with poly I:C were significant higher when compared to WT mice at 2 h ( fig. 3 h) .
Next, we analyzed the effect of PAR-1 deficiency on poly I:C induction of IFNβ, CXCL10, CCL5 and CXCL1 in the plasma. PAR-1 -/-mice had significantly lower levels of IFNβ and CXCL10 in the plasma 2 h after poly I:C treatment compared to WT mice ( fig. 4 b, d ). CCL5 plasma levels were lower in PAR-1 -/-mice than in WT mice but this difference was not statistically significant ( fig. 4 f) . As expected from the splenic data, the CXCL1 plasma levels were significantly higher in PAR-1 -/-mice than in WT mice 2 h after poly I:C injection ( fig. 4 h) .
Inhibition of Thrombin Is Associated with Reduced Poly I:C Induction of Antiviral Proteins in the Spleen and Plasma
Thrombin is the primary activator of PAR-1 in vivo [13] . Furthermore, poly I:C injection of the mice was associated with the increased activation of coagulation [12] . We observed a maximal activation of coagulation, as mea- sured by levels of circulating thrombin-antithrombin complexes, 4 h after poly I:C injection (data not shown). To determine if thrombin contributes to antiviral responses after poly I:C injection, WT mice were fed with the thrombin inhibitor dabigatran etexilate (10 g/kg chow) prior to poly I:C injection. The dabigatran etexilate treatment significantly reduced IFNγ, CXCL10, CCL5 and viperin but not IFNβ and IRF7 mRNA expression in the spleen 4 h after poly I:C injection of WT mice compared to placebo-treated WT mice ( fig. 5 a) . As observed with PAR-1 -/-mice, splenic CXCL1 mRNA expression was significantly increased with dabigatran etexilate compared to placebo-fed WT mice ( fig. 5 a) . Furthermore, CXCL10 protein levels in the spleen and plasma were significantly lower with dabigatran etexilate compared to in placebofed WT mice 4 h after poly I:C injection ( fig. 5 b, c) .
PAR-1 Deficiency Is Associated with Reduced Antiviral Responses in the Spleen after CVB3 Infection
TLR3-dependent signaling in macrophages was shown to mediate protection after CVB4 infection [20] .
We found that PAR-1 deficiency was associated with reduced innate immune responses in the heart in CVB3 myocarditis [4] . In addition, CVB3 can infect and persist in the spleen and macrophages but its replication is highly suppressed [35] [36] [37] . WT and PAR-1 -/-mice were infected with CVB3 and the response in the spleen and plasma was analyzed. Consistent with our poly I:C data, PAR-1 -/-mice expressed significantly lower levels of IFNβ, IRF7 and CCL5 mRNA in the spleen compared to WT mice 4 days after CVB3 infection ( fig. 6 a) . The expression of CXCL10 and viperin mRNA was also reduced in infected PAR-1 -/-mice spleens compared to WT mice spleens but this did not reach significance. There was no difference in IFNγ expression between the genotypes. Furthermore, splenic CXCL1 mRNA increased significantly in PAR-1 -/-mice spleens compared to infected WT mice spleens ( fig. 6 a) . CXCL10 protein levels were significantly reduced in the spleen but not in the plasma ( fig. 6 b, c) . As expected from the fact that CVB3 cannot replicate in macrophages, WT and PAR-1 -/-mice had similar levels of viral genomes ( fig. 6 d) , indicating that the differences in the expression of antiviral genes was not due to different levels of virus.
Inhibition of Thrombin Is Associated with a Reduced Antiviral Response in the Spleen after CVB3 Infection
In our recent paper, we showed that thrombin inhibition increased CVB3 myocarditis in mice due to a decrease in the innate immune response [4] . In this study, we found that thrombin inhibition reduced the poly I:C induction of antiviral gene expression in the spleen. To determine if thrombin signaling contributes to the antiviral response in the spleen in CVB3 infected mice, we treated WT mice with dabigatran etexilate or placebo and then infected them with CVB3 and measured the antiviral response at 4 days. As expected, thrombin inhibition resulted in a significant reduction of the splenic IFNγ, CXCL10, CCL5 and IRF7 but not viperin mRNA expression ( fig. 7 a) . IFNβ mRNA was reduced but this reduction did not reach significance ( fig. 7 a) . However, we did not observe any differences in the CXCL10 levels in the spleen or plasma ( fig. 7 b, c) . CXCL1 expression was increased in dabigatran-treated compared to placebo-treated mice 4 days after CVB3 infection ( fig. 7 a) . The difference in the antiviral response in the spleen was due to the effect of thrombin on gene expression but not on virus load, since the spleens of infected dabigatran etexilate-treated and placebo-treated mice showed comparable CVB3 genome levels ( fig. 7 d) .
Discussion
The immune and blood coagulation systems combine to combat infections [17, 18] . dsRNA or poly I:C activation of TLR3 induces type I IFN innate immune responses as well as inducing TF expression and the activation of coagulation [1, 3, 9, 10, 12, 17] . Here, we showed that PAR-1 deficiency is associated with a reduction in the poly I:C induction of IFNβ and CXCL10 expression in the spleen and plasma. This is likely due to reduced TLR3-mediated responses in the immune cells, including splenic macrophages and DCs. Consistent with this notion, we found that PAR-1-deficient BMMs, BMDCs and splenocytes expressed lower levels of IFNβ and CXCL10 in vitro when stimulated with poly I:C and PAR-1 agonist compared to WT cells. Interestingly, we found that PAR-1 deficiency is associated with higher CXCL1 expression after poly I:C challenge. In addition, thrombin inhibition of WT mice produced similar results to in PAR-1 -/-mice, suggesting that thrombin-dependent PAR-1 activation is important for the effective innate immune responses in the spleen. PAR-1 -/-mice treated with dabigatran etexilate and infected with CVB3 also showed a reduction in the antiviral response and an increase in CXCL1 compared with WT mice. Together, our results indicate that PAR-1 expression and the thrombin-PAR-1 pathway contribute to innate immune responses to poly I:C and viral infection.
TLR3 is activated by viral dsRNA reaching the endosomal compartment. This can occur when cells, such as macrophages and DCs, phagocytose dsRNA released into the extracellular space by dying virus-infected cells or when cells internalize viruses by receptor-mediated endocytosis [3] . Although normally restricted to the endosome, under certain conditions, TLR3 can be located on the cell surface [3, 4] . TLR3 is expressed throughout the spleen [6] . In this study, we showed that PAR-1 is required for the maximal poly I:C induction of the IFN innate immune pathway in the spleen. The differences in gene expression observed in the spleen of PAR-1 -/-mice may, in part, explain the decreased levels of IFNβ and CXCL10 levels in the plasma of poly I:C-treated PAR-1 -/-mice. This observation supports our recent findings and the proposed model of cooperative signaling between TLRs and PARs during infections [4, 5, 9, 10, 19] . The cells of the marginal zone of the spleen are the first to encounter the content of the blood, and may be the site where poly I:C is detected after i.p. injection [6] . Indeed, IFNβ was the major form of IFN produced in the red pulp and marginal zone of the spleen after poly I:C stimulation [25, 38] . The difference in the splenic innate immune response after poly I:C injection appears to be due to cooperative signaling of PAR-1 and TLR3 on immune cells within the spleen, since isolated splenocytes exhibited a similar response when stimulated with poly I:C and PAR-1 agonist ex vivo. Furthermore, for some virus species, it has been shown that nonfibroblast-like cells, such as splenic marginal-zone macrophages and DCs, are the primary cells that respond with type I IFN and IFN-response gene expression after infection [39] . In addition, the depletion of phagocytic splenic macrophages and DCs of the marginal zone markedly reduced antiviral responses including the IFN-response genes, CXCL10 and CCL5 [32] . However, we cannot exclude the possibility of signaling from other dsRNA receptors, such as melanoma differentiation-associated gene 5, which is also dependent on PAR-1 activation in vivo. This scenario does seem unlikely since we used nonliposome complexed, naked poly I:C, and TLR3 -/-mice showed a dramatically reduced response to poly I:C (data not shown).
Surprisingly, we observed that the CXCL1 expression was negatively regulated by PAR-1 in splenocytes and in mice. CXCL1 is the murine homolog of human IL-8. PAR-1 activation reduced CXCL1 expression in splenocytes when cells were stimulated with poly I:C, and cells from PAR-1 -/-mice expressed more CXCL1 after poly I:C stimulation. Furthermore, PAR-1 deficiency and thrombin inhibition increased CXCL1 expression in the spleen and plasma after poly I:C stimulation or CVB3 infection. Interestingly, it was shown that increased IRF3 activity was associated with higher levels of expression of IFNβ, CXCL10 and IRF7 but lower levels of CXCL1/IL-8 and other proinflammatory cytokines in the microglia and astrocytes [40, 41] . This was due to protein kinase Bdependent inhibition of NF-κB. In addition, PAR-1 activation was shown to activate protein kinase B [42] . Moreover, IFNβ was shown to suppress IL-8 gene expression by modulating NF-κB p65, and therefore reduced the binding to the κB element within the IL-8 promoter [43] .
These findings are in line with our recently proposed hypothesis that PAR-1 activation inhibits the NF-κB pathway after TLR3 stimulation [9] .
The TLR3-IFN pathway in immune cells, such as macrophages, was shown to limit viral replication of different viruses, such as CVB, influenza, poliovirus, rhinovirus, herpes simplex and HIV [3, 7, 8, 20, 31] . Furthermore, we and other authors have shown that viral infections lead to increased TF expression in infected tissue and the activation of coagulation [4, [9] [10] [11] 27] . In addition, poly I:C injection leads to the activation of coagulation in mice [12] . More recently, it was shown that known PAR-1-activating proteases, such as MMP1 and MMP13, are highly expressed in respiratory syncytial virus-infected mouse lungs and infected human lung epithelial cells in vitro [44] . Here, we showed that thrombin is one of the possible activators of PAR-1 after poly I:C injections. Inhibition of thrombin during in vivo poly I:C stimulation resulted in reduced IFNβ and IFNβ-response gene expression in the spleen and plasma. However, the dabigatran etexilate effect was weaker than the effect observed with a global PAR-1 deficiency, which suggests that other PAR-1 activators such as MMPs may also be involved in the in vivo response to poly I:C. Furthermore, PAR-1 deficiency and thrombin inhibition led to reduced IFN responses in the spleen of mice 4 days after CVB3 infection. The observed reduction was not due to differences in virus-dependent thrombin-PAR-1 signaling, since the infected WT mice, PAR-1 -/-mice, placebo-treated mice and dabigatran etexilate-treated mice showed comparable splenic CVB3 genome levels.
Interestingly, PAR-1 and PAR-2 have opposite effects on TLR3-dependent induction of IFNβ expression [9, 10, 45] . In contrast to PAR-1-deficient cells, PAR-2-deficient cells exhibit increased levels of IFNβ expression in response to poly I:C, and PAR-2 -/-mice are protected from CVB3 and influenza A/H1N1 infection [4, 5, 33] . We speculate that the innate antiviral response is stimulated by host proteases, such as thrombin and MMP13, whereas viral proteases may activate PAR-2 in an attempt to dampen the antiviral response to the virus.
With regard to the potential clinical significance of our findings, it is possible that interference with the PAR-1 pathway from direct thrombin inhibitors, such as dabigatran etexilate, MMP13 inhibitors or direct PAR-1 inhibitors, may increase the risk and severity of viral infection as we showed in a mouse CVB3 myocarditis model [4] . However, the importance of PAR-1 signaling might be only applicable for an initial viral infection or in immunocompromised individuals.
A different scenario may occur with virus infections that persist in the body and lead to chronic activation of the innate immune and clotting systems as observed in HIV [46, 47] . For instance, it was shown that, even under highly efficient antiretroviral therapy, an ongoing innate immune response and coagulation activation were associated with up to a 30-fold increase in mortality in HIV patients compared to uninfected controls [46, 48] . Despite undetectable virus levels, patients under antiretroviral therapy exhibit chronically elevated levels of type I IFNs, CXCL10 and coagulation markers, such as plasma TF and D-dimer [46] [47] [48] . In the case of a retroviral infection, anticoagulation and/or PAR-1 inhibition may reduce overall mortality of HIV-infected patients by directly affecting the activation of the coagulation system as well as dampen the activation of the coagulation-dependent immune system [47] . In line with our proposed mechanism, there are 2 ongoing clinical studies to use targeted anticoagulation therapy with the FXa inhibitor edoxaban (TACTICAL-HIV, NCT02339415) or the PAR-1 inhibitor vorapaxar (ADVICE, NCT02394730) in patients with HIV infection who are being successfully treated with combination antiretroviral therapy. Both studies will compare the safety and efficacy of either edoxaban or vorapaxar in reducing markers of cellular immune activation in HIV disease.
In summary, we show that PAR-1 activation contributes to poly I:C induction of TLR3/IFN responses in isolated macrophages and splenocytes and mice. Our results highlight the important crosstalk between the activation of coagulation and early innate antiviral responses in immune cells and the spleen in general.
